Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CD47 agonist peptides induce programmed cell death in refractory chronic lymphocytic leukemia B cells via PLCγ1 activation: evidence from mice and humans.
Martinez-Torres AC, Quiney C, Attout T, Boullet H, Herbi L, Vela L, Barbier S, Chateau D, Chapiro E, Nguyen-Khac F, Davi F, Le Garff-Tavernier M, Moumné R, Sarfati M, Karoyan P, Merle-Béral H, Launay P, Susin SA. Martinez-Torres AC, et al. Among authors: herbi l. PLoS Med. 2015 Mar 3;12(3):e1001796. doi: 10.1371/journal.pmed.1001796. eCollection 2015 Mar. PLoS Med. 2015. PMID: 25734483 Free PMC article.
Thrombospondin-1 Mimetic Agonist Peptides Induce Selective Death in Tumor Cells: Design, Synthesis, and Structure-Activity Relationship Studies.
Denèfle T, Boullet H, Herbi L, Newton C, Martinez-Torres AC, Guez A, Pramil E, Quiney C, Pourcelot M, Levasseur MD, Lardé E, Moumné R, Ogi FX, Grondin P, Merle-Beral H, Lequin O, Susin SA, Karoyan P. Denèfle T, et al. Among authors: herbi l. J Med Chem. 2016 Sep 22;59(18):8412-21. doi: 10.1021/acs.jmedchem.6b00781. Epub 2016 Sep 2. J Med Chem. 2016. PMID: 27526615
Homotrimerization Approach in the Design of Thrombospondin-1 Mimetic Peptides with Improved Potency in Triggering Regulated Cell Death of Cancer Cells.
Denèfle T, Pramil E, Gómez-Morales L, Levasseur MD, Lardé E, Newton C, Herry K, Herbi L, Lamotte Y, Odile E, Ancellin N, Grondin P, Martinez-Torres AC, Viviani F, Merle-Beral H, Lequin O, Susin SA, Karoyan P. Denèfle T, et al. Among authors: herbi l. J Med Chem. 2019 Sep 12;62(17):7656-7668. doi: 10.1021/acs.jmedchem.9b00024. Epub 2019 Aug 26. J Med Chem. 2019. PMID: 31403795
Antibody-dependent cellular cytotoxicity of the optimized anti-CD20 monoclonal antibody ublituximab on chronic lymphocytic leukemia cells with the 17p deletion.
Le Garff-Tavernier M, Herbi L, de Romeuf C, Nguyen-Khac F, Davi F, Grelier A, Boudjoghra M, Maloum K, Choquet S, Urbain R, Vieillard V, Merle-Béral H. Le Garff-Tavernier M, et al. Among authors: herbi l. Leukemia. 2014 Jan;28(1):230-3. doi: 10.1038/leu.2013.240. Epub 2013 Aug 20. Leukemia. 2014. PMID: 23958919 No abstract available.
Gain in the short arm of chromosome 2 (2p+) induces gene overexpression and drug resistance in chronic lymphocytic leukemia: analysis of the central role of XPO1.
Cosson A, Chapiro E, Bougacha N, Lambert J, Herbi L, Cung HA, Algrin C, Keren B, Damm F, Gabillaud C, Brunelle-Navas MN, Davi F, Merle-Béral H, Le Garff-Tavernier M, Roos-Weil D, Choquet S, Uzunov M, Morel V, Leblond V, Maloum K, Lepretre S, Feugier P, Lesty C, Lejeune J, Sutton L, Landesman Y, Susin SA, Nguyen-Khac F. Cosson A, et al. Among authors: herbi l. Leukemia. 2017 Jul;31(7):1625-1629. doi: 10.1038/leu.2017.100. Epub 2017 Mar 27. Leukemia. 2017. PMID: 28344316 No abstract available.
The optimized anti-CD20 monoclonal antibody ublituximab bypasses natural killer phenotypic features in Waldenström macroglobulinemia.
Le Garff-Tavernier M, Herbi L, de Romeuf C, Azar N, Roos-Weil D, Bonnemye P, Urbain R, Leblond V, Merle-Beral H, Vieillard V. Le Garff-Tavernier M, et al. Among authors: herbi l. Haematologica. 2015 Apr;100(4):e147-51. doi: 10.3324/haematol.2014.118083. Epub 2014 Dec 31. Haematologica. 2015. PMID: 25552707 Free PMC article. No abstract available.